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tributes	 to	 development	 of	 diastolic	 dysfunction,	 lean	 and	 obese	 ZSF1	 rats	were	
treated	with	deoxycorticosterone	acetate	implants	and	a	high-salt	diet	(DS)	to	induce	
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marked	by	 the	 inability	 to	adequately	contract	during	systole,	and	
HF	with	preserved	ejection	 fraction	 (HFpEF).	HFpEF	 is	 associated	
with	 impaired	 cardiac	 relaxation	 and	 increased	 passive	 cardiac	




This	 lack	 of	 evidence-based	 treatment	 options	 might	 find	 its	
origin	 in	 the	 complex,	 multifactorial	 disease	 aetiology	 of	 HFpEF.	
Development	and	progression	of	HFpEF	 is	associated	with	a	high	
prevalence	 of	 non-cardiac	 comorbidities	 and	 in	 previous	 studies	
it	was	proposed	that	these	comorbidities	could	provoke	a	state	of	
chronic	 systemic	 inflammation,	 leading	 to	 coronary	 microvascu-
lar	 dysfunction,	 oxidative	 stress,	 enhanced	 cardiomyocyte	 stiff-
ness	and	myocardial	 fibrosis.2	Obesity	and	hypertension	are	both	
highly	prevalent	 (84%	and	60%-80%,	 respectively)	 among	HFpEF	
patients.3,4	 It	has	been	demonstrated	that	both	comorbidities	can	
individually	contribute	 to	development	of	diastolic	dysfunction	 in	
rodent	 models.	 For	 example,	 deoxycorticosterone	 acetate-	 and	
salt-induced	 hypertensive	 rats	 developed	 perivascular	 fibrosis,	
and	concentric	cardiac	hypertrophy	accompanied	by	diastolic	dys-
function	in	addition	to	hypertension.5,6	Similarly,	in	leptin-deficient	














alone	 in	 reducing	morbidity	or	mortality	 in	subsets	of	 (obese)	pa-
tients	with	HFpEF.11
Here,	we	tested	the	hypothesis	that	metabolic	and	hypertensive	
disease	 act	 synergistically	 in	 development	 and/or	 progression	 of	
HFpEF.	For	this	purpose,	male	 lean	and	obese	ZSF1	rats,	of	which	
the	 latter	were	previously	 shown	 to	develop	diastolic	dysfunction	
between	week	10	and	20	of	natural	ageing,12,13	were	studied	from	
12	weeks	of	age.	Both	 lean	and	obese	 rats	were	 treated	with	de-
oxycorticosterone	acetate	 implants	plus	high-salt	 diet	 (DS)	or	pla-
cebo	from	19	to	26	weeks	of	age	to	induce	severe	hypertension.	DS	
treatment	was	limited	to	this	period	to	prevent	potential	progression	
to	 HFrEF.	 In	 addition	 to	 echocardiographic,	 metabolic	 and	 hemo-
dynamic	analyses,	 immunohistochemistry	and	RNAseq	on	LV	apex	














obtained	 from	 Charles	 River	 and	 housed	 in	 a	 temperature-	 and	





from	 18	 to	 26	 weeks	 of	 age	 echocardiography	 was	 performed,	










2%-2.5%	 for	 maintenance).	 Transthoracic	 echocardiography	 was	
performed	with	a	digital	ultrasound	machine	 (model	Sonos	5500,	




Mitral	 flow	 velocity	 tracings	 were	 obtained	 with	 pulsed-wave	
Doppler	 above	 the	 mitral	 leaflets.	 Tissue	 Doppler	 imaging	 (TDI)	
was	used	to	obtain	early	(e’)	diastolic	velocity	at	the	medial	mitral	
annulus.	 The	 recordings	 were	 averaged	 from	 three	 consecutive	
heartbeats.










receptor	mutation,	were	 studied	 from	12	 to	26	weeks	of	 age.	Both	
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Obesity,	 in	both	placebo-	and	DS-treated	rats,	caused	a	minor	
reduction	 in	 ejection	 fraction	 (EF),	 with	 the	 lowest	 EF	 (59%)	 ob-
served	in	the	DS-treated	obese	group	(Figure	1C).	Heart	rate	was	
reduced	 in	both	placebo-	 and	DS-treated	obese	 rats,	 and	 cardiac	




hypertension	both	 tended	 to	 increase	 LV	weight	 (LVW)	 and	 total	
heart	weight	(HW),	but	a	significant	increase	was	only	observed	in	










rats	and	DS-treated	obese	vs	DS-treated	 lean	 rats,	 a	 total	of	410	
and	146	genes	were	differentially	 expressed	 (FDR	<	0.1),	 respec-
tively	 (Figure	 1F-G,	 Table	 S2-S3).	 Conversely,	 in	 DS-treated	 lean	
rats	vs	placebo-treated	lean	rats	and	DS-treated	obese	rats	vs	pla-
cebo-treated	obese	rats,	a	total	of	1258	and	1504	genes	were	dif-
ferentially	expressed	 (FDR	<	0.1),	 respectively	 (Figure	1H-I,	Table	
S4-S5).
3.2 | Mitochondrial gene expression and apoptosis
Analyses	of	 transcription	profiles	with	 Ingenuity	Pathway	Analysis	
(IPA)	 indicated	 that	both	 risk	 factors	had	substantial,	 yet	opposite	










upstream	 regulator	 in	 placebo-treated	 obese	 vs	 lean	 rats	 (overlap	
P	=	2.66E-13/Z-score	=	2.95).	 Interestingly,	 it	was	among	the	most	
suppressed	 regulators	 in	DS-treated	 rats	 (overlap	P	 =	 5.37E-14/Z-
score=−3.97	and	overlap	P	=	7.73E-17/Z-score=−3.70	in	lean	+	DS	vs	
TA B L E  1  Model	characteristics	at	26	wk	of	age
 
Lean Lean + DS Obese Obese + DS P‐values
(n = 6) (n = 7) (n = 6) (n = 7) Obesity DS Interaction
Tibia	length	(mm) 40.8	±	0.5 40.0	±	0.4 38.1	±	0.4a 39.1	±	0.6 <.05 .93 .05
Body	weight	(g) 443	±	9 417	±	10 584	±	13a 607	±	10b <.05 .91 <.05
Cholesterol	(mM) 2.2	±	0.1 2.1	±	0.1 8.2	±	0.8a 9.1	±	0.7b <.05 .46 .34
Triglycerides	(mM) 1.5	±	0.2 1.1	±	0.2 23.8	±	4.0a 20.5	±	2.5b <.05 .44 .53
Glucose	(mM) 9.9	±	0.5 9.1	±	0.5 22.5	±	2.6a 14.0	±	1.6d <.05 <.05 <.05
Natriuresis	(μmol/d) 1484	±	191 10502	±	1126c 3260	±	422 14749	±	1463b,d <.05 <.05 .213
Natriuresis	
(μmol/d/100	g)
338	±	46 2546	±	300c 544	±	71 2419	±	213d .83 <.05 .378
SBP	(mm	Hg) 153	±	3 179	±	4c 150	±	1 213	±	5b,d <.05 <.05 <.05
Heart	rate	(bpm) 381	±	9 362	±	8 308	±	9a 292	±	6b <.05 <.05 .81
SV	(μL) 212	±	19 217	±	23 178	±	19 187	±	19 .13 .71 .90
CO	(mL/min) 81	±	7 79	±	8 55	±	6 55	±	5 <.05 .87 .92
CI	(mL/min/100	g) 18.2	±	1.6 18.7	±	1.7 9.5	±	1.2a 9.0	±	0.9b <.05 .99 .73
EF	(%) 73	±	2 70	±	3 65	±	1a 59	±	2b,d <.05 <.05 .48
E/e’ 15.9	±	0.9 17.5	±	0.6 20.5	±	0.6a 22.9	±	0.7b,d <.05 <.05 .55
LVW	(mg) 909	±	27 1139	±	64 1172	±	66 1490	±	116b,d <.05 <.05 .58







dObese	+	DS	vs	obese	P < .05. 
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lean	 and	obese	+	DS	 vs	 obese,	 respectively;	 Figure	2C,	 Table	 S6-
S8).	qPCR	analysis	of	established	KLF15	 targets	Hydroxyacyl-CoA	






equally	 affecting	 the	 different	 complexes	 of	 the	 electron	 trans-
port	 chain	 (Figure	 2D).	 Remarkably,	 DS-induced	 down-regulation	








The	 adaptations	 in	 transcription	 of	 mitochondrial	 genes	
raised	 the	 question	 whether	 this	 led	 to	 programmed	 cell	 death.	
Histological	analysis	of	activated	Caspase	3,	a	marker	of	early	apop-
tosis,	indicated	no	significant	changes	in	sub-endocardial	apoptosis	
(Figure	 S2A	 and	 C),	 although	 the	 apoptotic	 effect	 of	 DS-induced	
hypertension	showed	a	trend	(P	=	 .05;	Table	S9).	A	similar	pattern	




S9).	Noteworthy,	 the	apoptotic	cells	were	predominantly	 found	 in	
patchy	regions	(Figure	S2E).
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affected	 by	 both	 DS-induced	 hypertension	 and	 obesity	 individually,	
obesity	was	associated	with	an	elevated	cellular	cross-sectional	area,	but	
no	contribution	of	DS-induced	hypertension	was	observed	(Table	S9).
Transcription	 of	myosin	 heavy	 chain	 α	 (MYH6)	 and	 β	 (MYH7),	
defined	markers	for	myocardial	hypertrophy,17	resembled	this	pre-
dominant	 obesity-induced	 effect	 on	 cardiac	 remodelling.	 Obesity	
triggered	a	down-regulation	of	MYH6	and	an	up-regulation	MYH7	
(Figure	3C).	DS-induced	hypertension	also	reduced	the	expression	
of	 MYH6,	 though	 the	 effect	 size	 was	 more	 than	 two	 fold	 lower	





endoplasmic	 reticulum	 Ca2+-ATPase	 (SERCA2A)	 and	 phospholam-
ban	(PLN),	both	involved	in	calcium	reuptake	by	the	sarcoplasmic	re-
ticulum	during	diastole,	was	affected	as	well.	SERCA2A	expression	
was	 lowered	by	both	 comorbidities,	whereas	PLN	appeared	 to	be	
principally	affected	by	DS-induced	hypertension	(Figure	3D).	In	line	
with	SERCA2A,	transcription	of	ATPase,	Na+/K+	transporting	alpha	














respectively),	 and	 hypoxia-associated	 factor	 Vascular	 Endothelial	







cardiac	 inflammatory	 state,	 presence	 of	 CD3+	 T	 cells	 and	CD68+	
F I G U R E  4  Capillary	density.	(A)	Typical	examples	and	(B)	quantification	of	LV	microvasculature	(Lectin).	n	=	4-6,	*	P	<	.05.	(C)	QPCR	
analysis	of	cardiac	transcription	of	factors	involved	in	vascular	remodelling	ANGPT1,	ANGPT2	and	VEGFA.	n	=	5-7,	*	P < .05
8  |     BRANDT eT Al
macrophages	was	 evaluated.	 The	 number	 of	 CD3+	 T	 cells,	 repre-
senting	adaptive	immunity,	was	low	and	not	affected	by	obesity	or	
DS-induced	hypertension	(Figure	5A	and	5C,	Table	S9).	In	contrast,	
presence	 of	 CD68+	 macrophages,	 representing	 innate	 immunity,	
was	 markedly	 increased	 by	 DS-induced	 hypertension	 (Figure	 5B	
and	5D,	Table	S9).	Obesity	alone	had	no	effect,	but	in	combination	
with	DS-induced	hypertension	it	significantly	increased	macrophage	
presence,	 showing	a	 synergistic	 trend	 (interaction	P	 =	 .09).	 In	 line	
with	the	observed	DS-induced	apoptosis,	macrophage	presence	was	
mostly	seen	in	patchy	clusters	(Figure	5E).
3.6 | Fibrosis and TGFβ signalling




hypertension	 triggered	 a	 profound	 fibrotic	 response.	 The	 DS-in-
duced	fibrosis	appeared	to	be	aggravated	by	obesity,	although	no	sig-
nificant	interaction	was	observed	(interaction	P	=	.31;	Figure	6A-B,	
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in	the	hearts	of	DS-treated	vs	placebo-treated	rats	(Table	S10-S11).	
This	 predicted	 activation	was	 accompanied	 by	 transcriptional	 up-
regulation	 of	 TGFβ1	 and	TGFβ2	 (Figure	 6D)	 upon	DS-induced	 hy-
pertension.	Moreover,	 in	 addition	 to	 COL1A1,	 COL1A3	 and	 FN1,	
various	TGFβ	target	genes,	including	periostin	(POSTN)	and	osteo-




In	 line	 with	 previous	 reports,12,13	 ZSF1	 rats	 with	 a	 homozy-
gous	 leptin	 receptor	 mutation	 in	 our	 current	 study	 presented	
with	 metabolic	 derangements,	 including	 elevated	 body	 weight,	
hypercholesteremia,	 hyperglycaemia	 and	 hypertriglyceridemia.	
As	 anticipated,	 DS	 treatment	 triggered	 severe	 hypertension	 in	
both	 lean	 and	 obese	 ZSF1	 rats,	 and	 the	 combination	 of	 these	
factors	enabled	us	to	study	if	and	how	obesity	and	hypertension	
contribute	to	the	development	of	diastolic	dysfunction	at	a	func-
tional,	 histological	 and	 transcriptional	 level.	 From	 this	 study,	we	
can	 conclude	 that	 (a)	 obesity-associated	 derangements	 had	 the	
most	 predominant	 effect	 on	 development	 of	 diastolic	 dysfunc-
tion,	with	no	synergy	observed	between	obesity	and	DS-induced	
hypertension;	 (b)	 obesity	 also	 predominantly	 affected	 LV	 hyper-
trophic	 remodelling,	which	was	 associated	with	 increased	 foetal	
gene	expression	and	Ca2+-mediated	transcription;	(c)	capillary	rar-
efaction	was	 absent	 in	 all	 conditions,	whereas	 inflammation	and	
fibrosis	 occurred	 in	 response	 to	 DS-induced	 hypertension,	 with	
partial	synergy	observed	if	in	combination	with	obesity;	and	that	
F I G U R E  6  Fibrosis	and	TGFβ	signalling.	(A)	Typical	examples	and	(B)	quantification	of	histological	staining	for	cardiac	collagen	deposition	
(Picro	Sirius	Red).	n	=	6-7,	*	P	<	.05.	(C)	QPCR	analysis	of	cardiac	transcription	of	extracellular	matrix	components	COL1A1,	COL3A1	and	
FN1,	(D)	activators	of	TGFβ	signalling	TGFβ1	and	TGFβ2	and	(E)	transcriptional	targets	of	TGFβ	signalling	POSTN	and	SPP1.	n	=	5-7,	*	P < .05
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(d)	 obesity	 stimulated	enhanced	expression	of	 genes	 involved	 in	
FAO,	whereas	DS	treatment	led	to	an	overall	down-regulation	of	
genes	 involved	 in	 oxidative	 phosphorylation,	 implying	 that	 the	
comorbidities	triggered	different	mitochondrial	responses.	These	
findings	 do	 not	 support	 our	 initial	 hypothesis	 and	 illustrate	 im-
portant	phenotypical	differences	 in	comorbidity-induced	cardiac	
adaptation.















The	 lowering	of	CO	 induced	by	obesity	was	principally	 the	 re-
sult	of	a	lower	heart	rate,	which	is	consistent	with	diabetes-induced	
























and	 obesity.	 Transcriptional	 analysis	 supported	 the	 predominant	
obesity-induced	myocardial	maladaptation,	which	generally	occurs	
in	 the	presence	of	 reinitiated	 foetal	gene	expression	and	elevated	












even	 though	 crucial	 Ca2+-handling	 genes	 (ATP1A2,	 SERCA2A	 and	
PLN)	were	dysregulated	upon	DS-induced	hypertension.	Besides	its	
role	as	 second	messenger	 in	various	 signal	 transduction	cascades,	
Ca2+—and	its	removal	from	the	cytosol—plays	an	 important	role	 in	













which	contributes	 to	passive	 stiffness	and	LV	hypertrophy	via	 im-
paired	Protein	Kinase	G	activation.2	In	LV	sections	from	HFpEF	pa-
tients,	indeed	fibrosis	and	a	lower	capillary	density	were	observed,29 











to	 exposure	 to	 altered	 mechanical	 forces.31	 Additionally,	 DS-in-





the	 increased	urinary	TBARS	excretion	 in	 these	 rats	was	 presum-
ably	 not	 derived	 from	 vascular	 and	 neutrophilic	 NADPH-induced	
oxidative	stress.34	 Interestingly,	obesity	did	significantly	aggravate	
DS-induced	 macrophage	 presence	 and	 triggered	 up-regulation	 of	
many	 extracellular	matrix	 components	with	 a	 TGFβ	 signature,35,36 
suggesting	 putative	 interaction	with	DS-induced	 hypertension	 for	
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unexpected	 interaction.	 In	 fact,	 this	 may	 represent	 an	 important	
mechanism	through	which	interaction	between	these	comorbidities	
occurs.	Although	 the	elevated	body	mass	 in	obese	animals	mainly	




rats.	Nonetheless,	 from	 these	data	 it	 cannot	be	excluded	 that	 the	
observed	increase	in	inflammation	and	fibrosis,	the	only	parameters	














compared	with	 glucose	metabolism,43	 this	 could	 result	 in	 a	 lower	
ATP	bioavailability,	which	can	contribute	to	hampered	energy-con-
suming	diastolic	relaxation.44	The	increased	FAO,	which	may	partly	
occur	 in	 peroxisomes,45	 might	 also	 be	 causally	 related	 to	 the	 ob-












compared	 with	 those	 of	 placebo-treated	 rats,	 an	 overall	 down-





is	 causally	 related	 to	myocardial	 cell	 death,47,48	which	might	 ex-
plain	 the	 effect	 of	 DS	 on	 sub-endocardial	 TUNEL	 labelling.	 The	
relation	between	hypertension	 and	mitochondrial	 dysfunction	 is	
well	 described.49,50	 However,	 the	 present	 findings	 illustrate	 the	
different	effects	of	two	HFpEF	comorbidities	on	energy	homeo-





In	 summary,	 the	 present	 study	 shows,	 to	 our	 knowledge	 for	
the	 first	 time,	 how	 obesity	 and	 hypertension	 contribute	 to	 the	
development	of	diastolic	dysfunction.	Our	data	show	that	 intrin-
sic	metabolic	 derangements	 in	ZSF1	 rats	 have	 the	most	 evident	
effect	on	development	of	diastolic	dysfunction.	However,	from	a	
mitochondrial,	fibrotic,	and	inflammatory	point	of	view,	the	pres-
ence	of	 severe	hypertension	 appears	 to	have	 a	major	 impact	on	
disease	progression.	When	considering	therapeutic	interventions,	
it	 thus	 would	 seem	 extremely	 important	 to	 anticipate	 potential	
pathophysiological	 differences	 among	HFpEF	patients	 that	were	
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